Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its US FDA approval.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice.
Or get in touch at support@businessoffashion.com
if you experience difficulties.
The Trump administration on Friday will impose new tariffs of 10 percent and 12.5 percent on 60 trading partners, including…
The brand management firm will buy the denim label from owner Kontoor Brands for an initial $750 million payment and…
Givaudan’s second-quarter organic sales beat market estimates on Thursday, but its shares fell around 5 percent as litigation costs weighed…